News | October 16, 2012

SNMMI Issues Updated Guideline for Therapy of Thyroid Disease with I-131

October 16, 2012 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued an updated practice guideline on the treatment of thyroid cancer patients with I-131 (sodium iodide). Published in the October issue of the Journal of Nuclear Medicine (JNM), the guideline serves as an educational tool designed to assist trained practitioners in evaluating patients for therapy with I-131 for benign or malignant diseases of the thyroid gland, performing this treatment in a safe and appropriate manner, understanding and evaluating the pathological conditions resulting from the therapy, and reporting the outcomes of therapy.

“A great deal was changed in this new version of the guideline for I-131 therapy,” said Edward B. Silberstein, M.D., lead author of the guideline. “We have defined the levels of risk of thyroid cancer to patients which help determine the treatment needed, addressed the adverse effects of therapy, detailed the guidelines and regulations for patient release after I-131 therapy, and much more.”

Oral administration of I-131 has been a commonly accepted procedure for treatment of benign and malignant disorders of the thyroid since the 1940s. Physicians responsible for treating thyroid cancer patients should have an understanding of the clinical pathophysiology and natural history of the disease processes, be familiar with alternative forms of therapy, and be able to collaborate closely with other physicians involved in the management of the patient’s condition. The treating physician should either see patients in consultation with the physician assuming overall management of the patient’s condition or be prepared to assume that role. In the United States, the treating physician should be board-certified in nuclear medicine or able to document equivalent training, competency and experience in the safe use and administration of therapeutic I-131.

Licensure to possess I-131 and regulations regarding the release of patients treated with radioiodine, while governed by the Nuclear Regulatory Commission, vary from jurisdiction to jurisdiction. Physicians engaged in therapy with I-131 must be knowledgeable about, and in compliance with, all applicable laws and regulations. The facility in which treatment is performed must have appropriate personnel, radiation safety equipment and procedures available for waste handling and disposal, monitoring personnel for accidental contamination and controlling spread of I-131 to conform to state and federal regulations. All physicians engaged in therapy have a duty to ensure that their knowledge and competencies are up to date.

The SNMMI practice guideline for I-131 therapy for thyroid cancer reviews common clinical indications; qualifications and responsibilities of personnel; procedures and specifications of the examination; documentation and reporting; equipment specifications, quality control and improvement, safety, infection control and patient education concerns; and radiation dosimetry.

“In addition, we’ve also highlighted 14 issues that require further clarification, such as the diagnostic role of alternative imaging agents for thyroid cancer, the frequency and length of long-term follow-up after I-131 therapy, and others. SNMMI will work to address these issues in future versions of the guideline,” noted Silberstein.

Each practice guideline, representing a policy statement by SNMMI, undergoes a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Committee on Guidelines and SNMMI Board of Directors. SNMMI emphasizes that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document.

For more information: www.snmmi.org/guidelines

Related Content

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.
Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
The global radiation therapy market is expected to reach $10.11 billion in 2024, witnessing growth at a CAGR of 3.38%, over the period 2020-2024.
News | Proton Therapy | May 20, 2020
May 20, 2020 — ResearchAndMarkets.com has released its latest report, the ...
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

USask PhD bio-medical engineering student Farley Chicilo at the Canadian Light Source synchrotron at University of Saskatchewan. Photo courtesy of Canadian Light Source, University of Saskatchewan

News | Radiation Therapy | May 14, 2020
May 14, 2020 — An innovative radiation treatment t
Medical University of South Carolina researchers have developed and validated prediction tools, known as nomograms, that could be used to help prevent delays in the initiation of radiotherapy after surgery for head and neck cancer

 

Evan Graboyes, M.D., and his team believe their nomogram tools will improve survival rates for head and neck cancer patients. Photo courtesy of MUSC Hollings Cancer Center

 

News | Radiation Oncology | May 14, 2020
May 14, 2020 — More than 65,000 Americans are diagnosed annually with head and neck cancer, which most often occurs i
Due to ongoing health concerns related to the spread of the Coronavirus (COVID-19) as well as global travel restrictions, the American Association of Physicists in Medicine (AAPM) has decided to evolve the Joint AAPM/COMP (Canadian Organization of Medical Physicists) Meeting content into a virtual (completely online) meeting in place of the in-person meeting originally scheduled for July 12-16, 2020, in Vancouver, BC.
News | AAPM | May 11, 2020
May 11, 2020 — Due to ongoing health concerns related to the spread of the Coronavirus (...
Figure 1: CT image of lesions in different planes

Figure 1: CT image of lesions in different planes.

Sponsored Content | Case Study | Radiation Oncology | April 30, 2020 | By Christopher Bowen, M.S., DABR